Juno Therapeutics (JUNO) FDA-Determination Surprises Wall Street; Teva Pharma (TEVA) Raises Profits Guidance


Shares of Juno Therapeutics, Inc. (Nasdaq:JUNO) soared more than 20% in after-hours trading Tuesday as the company said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold – which was put in place by the government agency last week – on the mid-stage trial evaluating the efficacy and safety of its experimental therapy JCAR015 in adult patients with B cell acute lymphoblastic leukemia

JUNO stock closed the regular session at $27.79, up $0.46 (or +1.68%) and 3.99M shares of the biopharmaceutical company changed hands during the day, representing a large increase in activity versus its average volume (3m) of 1.48M

Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, has 105.54M Shares Outstanding and JUNO stock 52-week range is from $22.37 to $57.82 per share. At close on Tuesday, the biopharmaceutical company had a Market Capitalization of $2.88B



Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) stock closed at $52.46, up $1.53 (or 3.01%) with a total volume of 8.94M shares traded on Tuesday

Teva had raised its revenue and earnings outlook. After the closing bell, the global pharmaceutical company said that that it now expects second quarter 2016 revenues to be in the range of $4.9 billion to $5.0 billion and non-GAAP earnings of between $1.19 and $1.22 per diluted share, versus its previous guidance range of $4.8 billion to $4.9 billion in revenues and non-GAAP earnings of between $1.16 and $1.20 per diluted share, topping the Capital IQ Consensus Estimate of $1.17 earnings per share on revenues of $4.82 billion for the period

Teva Pharmaceutical, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, has 1.02B Shares Outstanding, Market Capitalization (intraday) of $47.76B and TEVA stock one-year range is between $48.01 and $72.31 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/